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Background: Chronic obstructive pulmonary disease (COPD) is a common disease 
characterized by airflow obstruction and lung hyperinflation leading to dyspnea and exercise 
capacity limitation.
Objectives: The present study was designed to evaluate whether an extra-fine combination 
of beclomethasone and formoterol (BDP/F) was effective in reducing air trapping in COPD 
patients with hyperinflation. Fluticasone salmeterol (FP/S) combination treatment was the 
active control.
Methods: COPD patients with forced expiratory volume in one second ,65% and 
plethysmographic functional residual capacity $120% of predicted were randomized to a double-
blind, double-dummy, 12-week, parallel group, treatment with either BDP/F 400/24 µg/day 
or FP/S 500/100 µg/day. Lung volumes were measured with full body plethysmography, and 
dyspnea was measured with transition dyspnea index.
Results: Eighteen patients were evaluable for intention to treat. A significant reduction in air 
trapping and clinically meaningful improvement in transition dyspnea index total score was 
detected in the BDP/F group but not in the FP/S group. Functional residual capacity, residual 
volume (RV) and total lung capacity significantly improved from baseline in the BDP/F group 
only. With regard to group comparison, a significantly greater reduction in RV was observed 
with BDP/F versus FP/S.
Conclusion: BDP/F extra-fine combination is effective in reducing air trapping and dyspnea 
in COPD patients with lung hyperinflation.
Keywords: small airways, chronic obstructive pulmonary disease, airflow obstruction
Introduction
Chronic obstructive pulmonary disease (COPD) is a common disease with airflow 
limitation due to both small airways obstruction and parenchimal damage.1 Although 
the measure of airflow limitation is a key point for the diagnosis and staging of COPD, 
static lung volumes have a better correlation with individually perceived symptoms and 
exercise capacity.2,3 Moreover, parameters of  hyperinflation show better correlation with 
patient-centered health outcomes than does forced expiratory volume in one second 
(FEV
1
).2 Indeed, the presence of hyperinflation in COPD, at rest or during exercise, 
can cause worsening of respiratory muscle function and gas exchange, and/or increase 
in work of breathing.4 Nonetheless, the degree of lung hyperinflation remains often 
undetected in the absence of detailed physiologic analysis.4 Daily physical activity 
of COPD patients is mainly associated with dynamic hyperinflation, regardless of 
severity classification5 and relief of exertional dyspnea following pharmacologic 
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therapy shows good correlation with a reduction in dynamic 
hyperinflation.6 Hence, targeting hyperinflation can make a 
difference to the patient.
In COPD patients, an inhaled glucocorticosteroid (ICS) 
combined with a long-acting β
2
-agonist (LABA) has an 
important role in clinical exacerbations of disease,7 improv-
ing lung function and health status.1 This combination 
therapy is of particular relevance in patients with frequent 
exacerbations associated with a rapid decline in lung func-
tion and increased mortality.8,9
The fixed combination of beclomethasone (BDP) 100 µg 
plus formoterol (F) 6 µg in a solution formulation is now 
available in a hydrofluoralkane pressurized metered-dose 
inhaler (pMDI). This formulation delivers the two drugs 
with an extra-fine particle size, which results in high lung 
deposition with the potential to target inflammation and 
bronchoconstriction, throughout the entire bronchial tree.10
The aim of this study was to assess the role of  beclometha-
sone and formoterol (BDP/F) extra-fine versus fluticasone/
salmeterol (FP/S) combination on lung function parameters 
and dyspnea in COPD patients with hyperinflation.
Methods
This trial was conducted in two Italian units of respiratory 
medicine (Parma and Pavullo n/F-Modena).
Patients
Patients were included if aged 40–70 years, current or past 
smokers (.20 pack years) with a confirmed diagnosis of 
COPD according to GOLD (Global initiative for chronic 
Obstructive Lung Disease) guidelines,1 a post-bronchodilator 
FEV
1
 ,65%, plethysmographic functional residual capacity 
(FRC) $120% of the predicted normal values, and an 
increase from baseline in post-bronchodilator FEV
1
 value of 
at least 5% (but less than 12%). Exclusion criteria included: 
asthma or positive response to the reversibility test (FEV
1
 
increase $12% and 200 mL after 400 µg salbutamol); COPD 
exacerbations and/or symptomatic infection of the airways 
in the previous 4 weeks requiring antibiotic therapy and or 
oral corticosteroid; history of clinically severe cardiovascular 
diseases, diabetes mellitus, and impaired hepatic and/or 
renal function; use of long-term oxygen therapy and patients 
undergoing a rehabilitation program. Moreover, patients 
treated with a higher daily dose of LABAs or ICS/LABA 
combination than that used in the study were excluded.
The trial was approved by the Ethics Review Board at each 
institution, and conducted in accordance with the Declaration 
of Helsinki and Good Clinical Practice Guidelines. All 
patients gave written informed consent.
study design
This was a double-blind, double dummy, randomized, parallel 
group study. During a 2-week run-in period, all previous 
medications with the exception of short-acting salbutamol 
for symptom relief were withdrawn and COPD patients 
were randomly assigned to a 12-week double-blind treatment 
period with either BDP/F 100/6 µg two inhalations twice 
daily or FP/S 250/50 µg one inhalation twice daily. No other 
bronchodilator, inhaled or systemic corticosteroid, or different 
combinations of these were permitted during the study.
To ensure the double-blind design, each patient was given 
a pMDI and a Diskus® (GlaxoSmithKline, London, UK) 
dry-powder inhaler (DPI), with either active drug or placebo 
(double dummy), in accordance with the randomization list. 
Inhalers containing drug or placebo were identical in shape 
and color. Randomization was in balanced-block design 
using a computerized list.
Morning dose started with two inhalations from the 
pMDI followed by one inhalation from the Diskus DPI, 
with a 30-second interval between inhalations; the same 
procedure was followed for the evening dose. Administration 
was  performed according to the inhaler instruction  leaflets 
provided by the sponsor. A total of five clinic visits were 
performed at screening, randomization, and after 4, 8, and 
12 weeks of treatment. At each visit, the morning dose 
was administered onsite at the hospital clinics under the 
investigator’s supervision to ensure that the inhalation 
technique used by the patients was correct.
Measurements
Whole-body plethysmography was measured in accor-
dance with a standard procedure11 at each visit, at least 
12 hours following the previous evening dose, 8 hours after 
the last administration of short-acting bronchodilators, 
before study drug intake (pre-dose) and 30 minutes after 
drug administration (post-dose). Diffusion lung capacity 
for carbon monoxide was measured at each visit before 
drug administration. At the second visit, baseline dyspnea 
index (BDI) was recorded prior to the first administration 
of study medication to assess chronic activity-related dys-
pnea, whereas change in dyspnea over time was evaluated 
by the transition dyspnea index (TDI) prior to dosing at 
subsequent visits.12 To measure the endurance time (ET), 
in seconds, an incremental cardiopulmonary exercise test 
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was also performed with cycle ergometer at the second visit, 
and constant-load tests were performed at 75% of the maxi-
mal work rate, as previously described,13 from the second 
visit onwards either pre-dose or 1 hour post dosing.
statistics
Data are expressed as mean ± standard error of the mean 
(SEM), unless otherwise specified. Due to the explorative 
nature of the study and the lack of data with BDP/F in COPD, 
no formal sample size calculation was performed. The analysis 
of covariance, with treatment and center as factors and baseline 
value as a linear covariate, was applied. The values measured 
in the randomization visit before study drug intake (pre-dose) 
were considered for baseline values. The adjusted means for the 
two groups at each visit and the adjusted treatment difference 
between groups at each visit were recorded. All analyses were 
performed with SAS®  System (SAS Institute Inc, Cary, NC), 
version 9.1.3, Service Pack 4. Statistical significance was set 
at 0.05 two tailed, and all analyses were performed on the 
intention-to-treat population (ITT).  Imputation of missing 
data was completed following last observation carried for-
ward method for post-baseline data.
Results
Twenty patients entered the run-in period between 2006 
and 2009, eighteen (15 males, age range 57–72 years, 
body mass index range 22.7–30.9 kg/m2) were randomized, 
and 14 completed the study (Figure 1). During the run-in 
period, one patient was lost to follow-up and one was not 
compliant to study protocol and was not randomized. All 
randomized patients were treated and evaluated for ITT. 
Patient compliance to the scheduled doses of study drugs was 
95% in both groups. Baseline lung function data of BDP/F 
and FP/S patient groups are presented in Table 1. Median 
(range) Medical Research Council and BDI scores were 2 
(2–5) and 2.5 (2–5), and 8 (3–9) and 7 (3–9), in the BDP/F 
and FP/S groups, respectively. Groups were well balanced 
at baseline, and no difference between groups was detected 
in clinical functional and anthropometric parameters.
All parameters related to air trapping showed an 
improvement in pre-dose measurements, although not 
statistically significant, with BDP/F treatment but not with 
FP/S (Table 2). In post-dose measurements FRC, residual 
volume (RV) and total lung capacity (TLC) significantly 
improved from baseline to week 12 in the BDP/F group 
N = 20
Patients screened
N = 18
Patients randomized
N = 6
Completed
N = 8
Completed
N = 9
Patients assigned to:
FP/S
N = 9
Patients assigned to:
BDP/F
N = 2
Screening failure
reasons:
1 lost to follow up
1 not cooperative with study
procedures
N = 3
Withdrawn reasons:
2 consent withdrawal
N = 1
Withdrawn reasons:
1 COPD exacerbation
1 knee pain
Figure 1 A flowchart representing patient flow. 
Abbreviations: BDP/F, beclomethasone dipropionate/formoterol; FP/S, fluticasone propionate/salmeterol.
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only (Table 3 and Figure 2). Similarly, a trend towards 
improvement in forced vital capacity (FVC) (P = 0.064), 
FRC/TLC (P = 0.059), and RV/TLC (P = 0.062) was detected 
in the BDP/F group but not in the FP/S group (Table 3 and 
Figure 2). With regard to group comparison, a significantly 
greater reduction in RV was observed with BDP/F versus 
FP/S (Table 3 and Figures 2 and 3).
A significant improvement in functional impairment 
TDI mean (SEM) score from baseline of 0.40 (0.17) in the 
BDP/F group (P = 0.033) and of 0.37 (0.17) in the FP/S 
group (P = 0.046) was detected. A significant improvement 
in magnitude of task of 0.33 (0.13) in the BDP/F group 
(P = 0.024) was shown, whereas the change in the FP/S 
group was of 0.22 (0.13) and was not significant (P = 0.110). 
No significant change was detected in magnitude of effort, 
which showed a change from baseline of 0.38 (0.22) in the 
BDP/F group (P = 0.122) and of 0.29 (0.22) in the FP/S 
group (P = 0.222). The TDI total score showed a significant 
and clinically relevant improvement from baseline of 1.144 
(0.46) in the BDP/F group (P = 0.026) but not in the FP/S 
group, for which the change was 0.86 (0.46) (P = 0.083) 
(Figure 4).
The mean ± SEM adjusted values of pre-dose and 
post-dose ET at end of treatment were not statistically 
different in the BDP/F group (477.2 ± 71.8 seconds and 
513.6 ± 79.2  seconds), compared with the FP/S group 
(398.9 ± 71.8 seconds and 475.6 ± 79.2 seconds).
Six adverse events were reported in five patients (three 
in the FP/S group and two in the BDP/F group). All these 
adverse events were considered not related to the study drugs 
and mild in severity apart from a COPD exacerbation in the 
FP/S group that was considered moderate and led to study 
discontinuation. Vital signs (blood pressure and heart rate) did 
not show clinically relevant changes over time in either group.
Discussion
This is the first study comparing the effects of two different 
ICS/LABA combinations on lung hyperinflation and 
 dyspnea in COPD. The two groups were well balanced in 
baseline characteristics including smoking habits, diffusion 
lung capacity, spirometry, and lung volumes. The FP/S 
combination was selected as active comparator instead of 
Table 2 Body plethysmography lung volumes (pre-dose)
Parameter BDP/F  
(n = 9)
FP/S  
(n = 9)
Difference P-value
IrV, L  0.10 ± 0.17 -0.20 ± 0.24 0.31 0.338
erV, L -0.08 ± 0.13  0.01 ± 0.13 -0.09 0.646
rV, L -0.28 ± 0.23  0.19 ± 0.23 -0.47 0.189
TLC, L -0.29 ± 0.21  0.10 ± 0.21 -0.38 0.231
FrC, L -0.31 ± 0.25  0.23 ± 0.25 -0.54 0.156
FVC, L  0.22 ± 0.20  0.02 ± 0.20 0.23 0.429
IVC, L  0.01 ± 0.17 -0.10 ± 0.17 0.11 0.679
rV/TLC, % -0.38 ± 2.17  1.83 ± 2.17 -2.21 0.495
FrC/TLC, % -1.62 ± 1.73  2.49 ± 1.73 -4.12 0.127
Note: Data are adjusted mean ± standard error of the mean; changes from baseline 
to the last visit before study drug intake (pre-dose). 
Abbreviations: BDP/F, beclomethasone dipropionate/formoterol; FP/S, fluticasone 
propionate/salmeterol; IrV, inspiratory reserve volume; erV, expiratory reserve 
volume; rV, residual volume; TLC, total lung capacity; FrC, functional residual 
capacity; FVC, forced vital capacity; IVC, inspiratory vital capacity.
Table 3 Body plethysmography lung volumes (post-dose)
Parameter BDP/F  
(n = 9)
FP/S  
(n = 9)
Difference P-value
IrV, L  0.42 ± 0.26 -0.01 ± 0.36 0.43 0.372
erV, L -0.05 ± 0.10 -0.02 ± 0.10 -0.03 0.862
rV, L -0.77 ± 0.29*  0.14 ± 0.29 -0.91 0.049
TLC, L -0.57 ± 0.26*  0.20 ± 0.26 -0.78 0.063
FrC, L -0.75 ± 0.32*  0.23 ± 0.32 -0.95 0.062
FVC, L  0.31 ± 0.15  0.11 ± 0.15 0.20 0.395
IVC, L  0.20 ± 0.13  0.06 ± 0.13 0.14 0.479
rV/TLC, % -4.76 ± 2.35  0.65 ± 2.35 -5.40 0.137
FrC/TLC, % -4.62 ± 2.25  1.28 ± 2.25 -5.90 0.096
Notes: Data are adjusted mean ± standard error of the mean; changes from baseline 
to the last visit after study drug intake (post-dose). *P , 0.05 versus baseline. 
Abbreviations: BDP/F, beclomethasone dipropionate/formoterol; FP/S, fluticasone 
propionate/salmeterol; IrV, inspiratory reserve volume; erV, expiratory reserve 
volume; rV, residual volume; TLC, total lung capacity; FrC, functional residual 
capacity; FVC, forced vital capacity; IVC, inspiratory vital capacity.
Table 1 Baseline lung function data of the patients
Parameter BDP/F  
(n = 9)
FP/S  
(n = 9)
FeV1, L  1.27 ± 0.16  1.07 ± 0.11
FeV1, % predicted  45.1 ± 5.0  40.0 ± 3.0
FVC, L  2.80 ± 0.31  2.42 ± 0.27
FVC, % predicted   77 ± 7   72 ± 6
FeV1/FVC, %   45 ± 3   45 ± 3
FrC, L  5.90 ± 0.75  5.84 ± 0.38
FrC, % predicted 173.0 ± 21.0 186.3 ± 10.0
rV, L  4.73 ± 0.76  4.82 ± 0.28
rV, % predicted 201.4 ± 34.0 224.5 ± 13.0
TLC, L  7.90 ± 0.79  7.59 ± 0.49
TLC, % predicted 125.1 ± 10.0 131.4 ± 7.0
rV/TLC, % 58.22 ± 4.69 64.00 ± 2.29
FrC/TLC, % 73.65 ± 2.68 76.92 ± 1.33
DLCO, mL/mmhg/min 11.80 ± 3.06 11.66 ± 1.64
Notes: Data are mean ± standard error of the mean, measured in the randomization 
visit before study drug intake (pre-dose). No significant difference between groups 
was found in any parameter. 
Abbreviations: BDP/F, beclomethasone dipropionate/formoterol; FP/S, fluticasone 
propionate/salmeterol; BMI, body mass index; FeV1, forced expiratory volume in one 
second; FVC, forced vital capacity; FrC, functional residual capacity; rV, residual 
volume; TLC, total lung capacity; DLCO, diffusion lung capacity for carbon 
monoxide; DLCO/VA, diffusion lung capacity for carbon monoxide corrected for 
alveolar volume.
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Figure 2 Percentage changes from baseline in lung function parameters measured after drug intake (post-dose) in the last visit.
Notes: *Denotes P , 0.05 versus baseline; §denotes P , 0.05 versus FP/s. 
Abbreviations: FrC, functional residual capacity; TLC, total lung capacity; FVC, forced vital capacity; rV, residual volume; BDP/F, beclomethasone dipropionate/formoterol; 
FP/S, fluticasone propionate/salmeterol.
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Figure 3 Individual patient changes from baseline to study end (post-dose) in 
residual volume.
Note: *Denotes P , 0.05 between groups. 
Abbreviations: BDP/F, beclomethasone dipropionate/formoterol; FP/S, fluticasone 
propionate/salmeterol.
placebo for ethical reasons and to provide clinically relevant 
information as this is one of the most used drugs for COPD 
patients in clinical practice.
The main findings of this study are that BDP/F improves 
lung function parameters related to air trapping and dyspnea 
in COPD patients. Body plethysmography measurements 
showed significantly improved FRC, TLC, and RV in 
BDP/F-treated patients, with a significantly greater reduction 
in RV compared with FP/S. These findings on reduction of 
RV and FRC are important determinants of improvement 
of dyspnea in COPD.14 Since this is the first data provided 
with BDP/F combination on lung hyperinflation, we can 
assume that the extra-fine formulation of BDP/F is likely to 
be one of the reasons for this effect, as the small particles 
delivered easily reach the small airways, with a uniform 
anti-inflammatory and bronchodilating effect. Indeed, periph-
eral airways obstruction is known to cause progressive “air 
trapping” during expiration, worsening of perceived dyspnea, 
and limitation of exercise capacity in COPD patients.1
The greater efficacy of BDP/F compared with FP/S 
in reducing air trapping as observed in this study is in 
agreement with previous data. In asthmatics treated with 
the same daily doses of the same combinations, Papi and 
colleagues, in a randomized controlled trial, showed a 
significant increase in FVC with BDP/F when compared 
with FP/S.15 Moreover, Scichilone et al showed a reduc-
tion in closing capacity consistent with a reduction in 
air trapping with BDP/F but not with FP/S.16 A recently 
published large randomized controlled study showed a 
comparable efficacy of BDP/F extra-fine combination and 
budesonide/formoterol (BUD/F) combination in COPD 
patients.17 BDP/F treatment for 48 weeks improved pul-
monary function and reduced symptoms compared with 
formoterol, improved the walking distance measured with 
the 6-minute walking test, improved quality of life, and was 
safe and well tolerated. Moreover, no significant difference 
was detected in any outcome between BDP/F extra-fine 
combination and BUD/F combination. It is noteworthy 
that a significant improvement in FVC was detected in 
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COPD patients treated with BDP/F and not in those treated 
with BUD/F or F alone.17
As regards other lung function parameters measured in the 
present study, a trend towards improvement was shown in the 
BDP/F group in FVC, FRC/TLC, and RV/TLC, and a trend 
for difference between groups was detected in FRC and TLC 
favoring BDP/F. Nonetheless, the number of patients was not 
enough to draw definitive conclusions on the different effects 
of the two investigated combinations on lung hyperinflation. 
Indeed, the inclusion criteria of high FRC, as a sign of resting 
hyperinflation, limited the potential for recruitment.
Interestingly, the present study demonstrates that BDP/F 
reduced TDI-dyspnea in terms of functional impairment, 
magnitude of task, and total score, whereas FP/S improved 
only functional impairment. Moreover, the increase in TDI 
total score with BDP/F was greater than 1 unit, a change that 
is considered clinically relevant.18
The results of this study were achieved with a lower 
daily dose of corticosteroid in BDP/F extra-fine combination 
(400 µg) compared with FP/S (500 µg), due to the extra-fine 
formulation resulting in a greater efficacy per microgram of 
steroid, in agreement with previous studies.16,19,20 The use 
of a combination with a low corticosteroid dose can be of 
particular relevance in COPD patients as side effects of ICS 
are dose-dependent, with an increased risk of pneumonia 
recently highlighted in a study with high-dose FP/S.21
It could be argued that the greater efficacy of BDP/F 
observed in the present study could be related to the 
characteristics of F and S in terms of onset of action. Actually, 
the improvements in air trapping related parameters were more 
evident in post-dose measurements, even if the trend for a 
greater effect with BDP/F than with FP/S is numerically evident 
even in pre-dose measurements. Therefore, a contribution of 
the bronchodilator component of each combination to the 
effect on lung function is likely, and we cannot exclude that 
this contributes to the between-group differences detected. 
Anyway, it has been shown that both F and S reach a maximum 
increase in FEV
1
 and IC in COPD patients 30 minutes after 
dosing, with no further improvement at 60 and 120 minutes 
thereafter,22 thus making it unlikely that the major reason 
for the differences is the onset of action of the two LABAs. 
Nevertheless, it has been shown in human small airways that 
formoterol has a higher intrinsic efficacy in reversing the 
carbachol-induced contraction as compared with salmeterol.23 
This could support the explanation of a greater efficacy due 
to pharmacological activity on small airways of the extra-fine 
BDP/F combination. It is noteworthy that the differences in 
favor of BDP/F in dyspnea improvements were detected in pre-
dose evaluation of dyspnea with the TDI score, thus suggesting 
that the difference between groups was evident even when the 
effect of the LABA was not present. We do not have all the 
data to conclude that the greater effect on air trapping of the 
BDP/F combination is due to formoterol, to BDP, or to the 
extra-fine formulation reaching the small airways.
In conclusion, this study shows the efficacy on lung 
air trapping and perceived dyspnea of extra-fine BDP/F 
0
Functional
impairment
*
*
*
*
Magnitude
of task
Magnitude
of effort
Total
score
*P < 0.05
BDP/F
FP/S
Threshold for
clinical relevance
0.2
0.4
0.6
0.8
1
1.2
Figure 4 Transition dyspnea index score.
Note: *Denotes P , 0.05 versus baseline. 
Abbreviations: BDP/F, beclomethasone dipropionate/formoterol; FP/S, fluticasone propionate/salmeterol.
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combination – when compared with FP/S – in COPD patients. 
An improvement on patients’ daily performance with this 
combination drug could therefore be assumed. Larger studies 
will confirm the precise role of BDP/F and its potential 
advantages as compared with the other available treatments 
in the long-term management of COPD patients.
Note
This study was registered in the Italian Registry for Clinical 
Trials.24 The registration number is: 2005-005857-23.
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